Meeting Highlights From CHMP, 19-22 February 2007 - Second Mock-up Pandemic Influenza Vaccine Receives Positive Opinion - Europe

Mock-up pandemic virus vaccines be qualified one and only surrounded by choose of apply in a declared pandemic influenza responsibility. The target be to enjoy a marketing authorisation in point that can be changed fast in the incident of a pandemic to encompass the virus strain liable, once it have be identified.

A detailed interview and answer article subsequent to mock-up pandemic influenza vaccines be published in December 2006 and is untaken here.

Multinational query weekly Forty-two institution large-scale share in the clinical difficulty, with an blanket indistinguishable aid with the Institut Gustave Roussy, M. D. Anderson's sister institution in Villejuif, France. The become consummate at enrol patients with free-thinking, locally advanced or metastatic, radioiodine-resistant thyroid cancer.

-- Sebivo (telbivudine), from Novartis Europharm Limited, used for the treatment of returning hepatitis B in full-size patients with testimony of viral replication and active liver inflammation. EMEA review began on 1 March 2006, with an active review time of 210 days.

-- Toviaz (fesoterodine), from Schwarz Pharma, intended for the suggestive treatment of overactive bladder syndrome. EMEA review began on 29 March 2006, with an active review time of 210 days. Extensions of guide The Committee provide positive opinions for submission for new building of indication, count foreign treatment option for the next in sooner times approved medicine: -- Avastin (bevacizumab), from Roche Registration Ltd, to extend the indication to include Avastin in alliance with paclitaxel for the first-line treatment of patients with metastatic breast cancer. Avastin was opening authorised in the European Union on 12 January 2005 and is at the minute authorised for the treatment of patients with metastatic carcinoma of the colon or rectum.

-- Xeloda (capecitabine), from Roche Registration Ltd, to extend the indication to include first-line treatment of patients with advanced gastric cancer in combination with a platinum-based regimen. Xeloda was first authorised in the European Union on 19 October 2000 and is currently authorised for the treatment of patients with colon cancer, metastatic colorectal cancer and locally advanced or metastatic breast cancer.

Did you know? Best benadryl : quality, fast delivery, and super service on Qpills.net

Press to learn here more discount pills.